Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONTAK in previously treated indolent B-cell NHL
NCT00051025Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2000
- Primary completion
- Jan 2001
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of denileukin diftitox in B-cell non-Hodgkin lymphoma, sponsored by Eisai Co., Ltd. Primary endpoint: Objective Clinical Response (Complete Response or Partial Response) at 24 weeks. Started May 2000; status: completed.
02
Drugs
denileukin diftitox
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00051025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051025.